Giles Platford on Takeda’s 5 Year Deal with WFH for The Humanitarian Aid Program!
Giles Platford, President, Plasma-Derived Therapies Business Unit at Takeda and Chair of the Global Executive Board at PPTA, reposted from World Federation of Hemophilia on LinkedIn:
”I’m proud to share this important milestone: Takeda has renewed its 5-year agreement with the WFH and WFH_USA—furthering our support for the WFH Humanitarian Aid Program!
Together with other partners, we are working to expand access, drive equity, and change lives for people living with inherited bleeding disorders globally.”
Quoting World Federation of Hemophilia‘s post:
”The WFH and WFH USA are pleased to announce that Takeda has signed a 5-year agreement renewal with the WFH Humanitarian Aid Program from 2026 to 2030!
The agreement is for the donation of treatment product, as well as a financial commitment to cover it’s handling, storage and shipping. Learn more.”
Stay updated with Hemostasis Today.
-
Nov 9, 2026, 13:48PF4-ELISA–Negative HIT: Are We Missing a New Class of Anti-PF4 Immunothrombotic Disease?
-
Nov 9, 2026, 13:07Nandini Sadasivam: Gene Therapy for Sickle Cell Disease and Thalassaemia
-
Nov 9, 2026, 13:04Raising Awareness of Bleeding Disorders in Women and Girls – EHC
-
Nov 9, 2026, 12:59Rahul Bohra: Exploring the Complex Mechanisms of Sickle Cell Disease
-
Nov 9, 2026, 12:53Three Years of Movement and Thrombosis Awareness in the Czech Republic – World Thrombosis day
-
Nov 9, 2026, 12:51Octavio Marques Pontes-Neto: Intensive Blood-Pressure Control Reduces Cardiovascular Events After Ischemic Stroke
-
Nov 9, 2026, 12:49Irma Bagdoniene: What Really Makes Us Live Longer
-
Nov 9, 2026, 12:47Imo Akpan: Announcing the 2027 Women’s Hematology Summit
-
Nov 9, 2026, 12:45Shadi Yaghi: Rethinking Antithrombotic Therapy After Stroke